Fotios Loupakis

基本信息

Career Trajectory

Bio

Focus on GI malignancies. More than 200 publications (PubMed with Impact Factor), mainly on advanced colorectal cancer. Principal investigator of several phase 2 and 3 randomized trials.

Research Interests

Papers共 565 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

The Role of Social Media in Fueling Bias in Oncology

Raffaele Giusti, Gennaro Daniele,Fotios Loupakis

JAMA oncology (2025)

Cited0Views0WOSBibtex

Supplementary Tables S1-S19 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

crossref（2024）

Cited0Views0Bibtex

Supplementary Figure S1 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

crossref（2024）

Cited0Views0Bibtex

Supplementary Video S2 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

crossref（2024）

Cited0Views0Bibtex

Supplementary Figure S3 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

crossref（2024）

Cited0Views0Bibtex

Supplementary Figure S5 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

crossref（2024）

Cited0Views0Bibtex

Supplementary Figure S6 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

crossref（2024）

Cited0Views0Bibtex

Data from Circulating Microrna Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p As a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

CLINICAL CANCER RESEARCHno. 10 (2024): 2140-2159

Cited3Views0WOSBibtex

Supplementary Figure S2 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

crossref（2024）

Cited0Views0Bibtex

Correlation of Gut Dysbiosis Biomarkers and Peripheral Thyroid Hormones Conversion in Patients with (pts) Advanced Lung Cancer

Adele Bonato,Lorenzo Belluomini,Carolina Alves Costa Silva,Marine Fidelle,Roxanne Birebent, Federica Gattazzo,Claudia Parisi,Jordi Remon Masip,Pernelle Lavaud,David Planchard,Mihaela Aldea,Benjamin Besse,Fabrice Barlesi,Fotios Loupakis,Laurence Zitvogel,Lisa Derosa

Journal of Clinical Oncologyno. 16_suppl (2024): e20517-e20517

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn

Medical Director

Papers共 565 篇Author StatisticsCo-AuthorSimilar Experts